Boston Scientific Corp. BSX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Boston Scientific Corp. (BSX) Business Model and Operations Summary
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Key Insights
Boston Scientific Corp. (BSX) Core Market Data and Business Metrics
Latest Closing Price
$101.24Market Cap
$149.58 BillionPrice-Earnings Ratio
80.99Total Outstanding Shares
1.48 Billion SharesTotal Employees
53,000Dividend
No dividendIPO Date
May 18, 1992SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
New York Stock ExchangeHeadquarters
300 Boston Scientific Way, Marlborough, MA, 01752-1234
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-5.69 Billion |
| Exchange Gains/Losses | $-11 Million |
| Net Cash Flow | $-449 Million |
| Net Cash Flow From Investing Activities | $-5.69 Billion |
| Net Cash Flow, Continuing | $-438 Million |
| Net Cash Flow From Financing Activities, Continuing | $1.81 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $1.49 Billion |
| Revenues | $16.75 Billion |
| Costs And Expenses | $14.46 Billion |
| Diluted Earnings Per Share | $1.25 |
| Operating Expenses | $8.89 Billion |
| Other Operating Expenses | $2.90 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-15 Million |
| Comprehensive Income/Loss | $2.06 Billion |
| Comprehensive Income/Loss Attributable To Parent | $2.08 Billion |
| Other Comprehensive Income/Loss | $218 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $233 Million |
| Liabilities And Equity | $39.40 Billion |
| Other Non-current Assets | $22.50 Billion |
| Noncurrent Assets | $32.48 Billion |
| Current Assets | $6.92 Billion |
| Noncurrent Liabilities | $10.99 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||